Here’s why Citi says crypto prices have been weak recently
Director Jeffrey P Rydin of Alphatec Holdings, Inc. (NASDAQ:ATEC) sold 200,000 shares of common stock on November 3, 2025, for $19.32 per share, totaling $3.86 million. Following the transaction, Rydin directly owns 385,441 shares of Alphatec Holdings .The sale comes amid ATEC’s remarkable 114.81% year-to-date price return, with shares currently trading at $19.72. InvestingPro analysis indicates the stock may be overvalued compared to its Fair Value assessment, despite receiving a "GOOD" overall financial health rating. Analysts maintain a bullish outlook with price targets ranging from $16 to $25. Discover more insights in ATEC’s comprehensive Pro Research Report, available among 1,400+ detailed company analyses on InvestingPro.
In other recent news, Alphatec Holdings reported impressive third-quarter 2025 earnings, with significant improvements in both revenue and earnings per share (EPS). The company posted an EPS of $0.03, surpassing the expected loss of $0.04, marking a surprising 175% improvement. Revenue for the quarter reached $197 million, representing a 30% increase compared to the previous year. This performance was bolstered by a 31% growth in surgical revenue and a 29% rise in EOS imaging technology revenue. Additionally, Alphatec experienced nearly 30% growth in surgical volume, with established territories and new surgeon users both seeing considerable increases. In light of these results, Piper Sandler and Canaccord Genuity both raised their price targets for Alphatec to $25, maintaining their Overweight and Buy ratings, respectively. These developments highlight Alphatec’s continued market share gains in the spine surgery sector.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.